logo
Plus   Neg
Share
Email

Novartis: Sandoz To Commercialize OIC Drug Rizmoic In Key European Countries

Swiss drug major Novartis AG (NVS) announced Thursday that Sandoz has signed an agreement with Japanese pharmaceutical company Shionogi & Co Ltd for commercialization of Rizmoic (naldemedine) in the key European markets of Germany, the UK and the Netherlands, plus right of first refusal for certain other European markets.

Under the terms of the agreement, Sandoz will be responsible for commercializing Rizmoic in Germany, the UK and the Netherlands and Shionogi will be responsible for its manufacturing and development. Further details of the deal are not being disclosed.

Rizmoic, a once-daily 200-microgram oral tablet discovered and developed by Shionogi, is an innovative medicine indicated to treat opioid induced constipation or OIC in adult patients previously treated with a laxative. OIC is a prevalent and distressing side-effect of opioid therapy that does not respond reliably to treatment with conventional laxatives.

Shionogi announced on February 22, 2019 that it had received EU marketing authorization for Rizmoic.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
NetApp Inc. (NTAP) Wednesday reported a fourth-quarter profit that fell short of Wall Street estimates, as revenues slipped 3 percent. Shares of the company slipped 6% in extended trading session after its first-quarter outlook was also short of current expectations. Sunnyvale, California-based NetApp... The release of $20 bill featuring Harriet Tubman, an American abolitionist and political activist, has been postponed. The redesign of the $20 bill featuring Tubman will no longer be unveiled in 2020, Treasury Secretary Steven Mnuchin said. The government was planning to unveil the redesigned $20... An analyst at Goldman Sachs Inc. has warned that Apple Inc.'s earnings could drop by 29 percent if China were to retaliate in the trade war against the U.S. with a ban on sales of Apple products in that country. The iPhone maker's China business accounted for 17.6 percent of its total sales in the recent second quarter.
Follow RTT